Affiliation: National Institutes of Health
- Potential use of lipoxygenase inhibitors for cancer chemopreventionV E Steele
Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
Expert Opin Investig Drugs 9:2121-38. 2000..Based on currently available data, it is expected that the prevention of lung and prostate cancer will be initially studied in human trials of LO inhibitors...
- Correlation between electron-donating ability of a series of 3-nitroflavones and their efficacy to inhibit the onset and progression of aberrant crypt foci in the rat colonVernon E Steele
Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892 7322, USA
Cancer Res 62:6506-9. 2002..The above correlations may be of predictive value in the search for new chemoprotective agents. The overall molecular mechanism of the inhibition of ACF by the 3-nitroflavones under study appears to involve redox reactions...
- Development of cancer chemopreventive drugs based on mechanistic approachesVernon E Steele
National Cancer Institute, EPN 2108, MSC 7322, 9000 Rockville Pike, National Institutes of Health, Bethesda, MD 20892 7322, USA
Mutat Res 591:16-23. 2005..Each cancer type, organ location, or individual genetic background may require a custom combination of prevention strategies to be successful...
- Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cellsVernon E Steele
Endocrine Section, Laboratory of Clinical Investigation, Division of Intramural Research, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD 20892, USA
Anticancer Res 26:3205-15. 2006..Because DHEA can be converted to androgens or estrogens, such use may promote prostate cancer. In this study, the effects of DHEA were compared with those of DHT using gene expression array profiles in human LNCaP prostate cancer cells...
- The use of animal models for cancer chemoprevention drug developmentVernon E Steele
Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA
Semin Oncol 37:327-38. 2010..Whether validated or not, animal efficacy data remain central to the clinical trial decision-making process...
- Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanismAnne Shilkaitis
Department of Surgical Oncology, University of Illinois, 840 S, Wood Str, Chicago, IL 60612, USA
Breast Cancer Res 7:R1132-40. 2005..Here we examine whether DHEA and its analog DHEA 8354 can suppress the progression of hyperplastic and premalignant (carcinoma in situ) lesions in mammary gland toward malignant tumors and the cellular mechanisms involved...
- Challenges in clinical prostate cancer: role of imagingGary J Kelloff
Division of Cancer Treatment and Diagnosis, Cancer Imaging Program, National Institutes of Health, National Cancer Institute, Bethesda, MD 20852, USA
AJR Am J Roentgenol 192:1455-70. 2009..The overarching issue in prostate cancer is distinguishing lethal from nonlethal disease. New technologies and fresh uses for established procedures make imaging effective in both assessing and treating prostate cancer...